Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
JAMA Network Open|April 10, 2026
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerMeghna S Trivedi, Joseph M Unger, N Lynn Henry, et al.Journal for Immunotherapy of Cancer|August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.British Journal of Clinical Pharmacology|April 25, 2015
In vivo assessment of the metabolic activity of CYP2D6 diplotypes and allelesDaniel L Hertz, Anna C Snavely, Howard L McLeod, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.The Oncologist|May 27, 2016
Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing ToxicityDaniel L Hertz, Allison Deal, Joseph G Ibrahim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast CancerAndres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter studyWilliam J Irvin, Christine M Walko, Karen E Weck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.Pharmacogenomics|December 19, 2009
Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual careTejinder K Rakhra-Burris, J Todd Auman, Patricia Deverka, et al.The New England Journal of Medicine|June 4, 2025
Omitting Regional Nodal Irradiation after Response to Neoadjuvant ChemotherapyEleftherios P Mamounas, Hanna Bandos, Julia R White, et al.Pageof 7